【康辰药业:KC1086联合疗法获临床试验通知书,拟开展Ⅱ期研究】康辰药业公告,公司自主研发的1类创新药KC1086拟用于晚期复发或转移性实体瘤治疗。公司近日收到国家药监局核准签发的临床试验通知书,同意KC1086联合氟维司群在HR+/HER2-局部晚期或转移性乳腺癌中开展临床研究;公司拟开展该联合方案Ⅱ期临床研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.